-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over th

DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062Intern

DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today confirmed that April 11, 2025 will be the effective date for the Company's previously announced Ratio Change on its American Depositary Shares ("ADS") -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The objective of this action is to increase the per share market price of the Company's ADSs to comply with Nasdaq's $1.00 minimum bid price per share requirement and maintain the Company's listing on The Nasdaq Capital Market. Th

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells. "The data presented at ACC.25 continue to underscore the therapeutic value of icosapent ethyl (IPE) and EPA in potentially addressing known pathways of cardiovascular (CV) risk beyond LDL lowering for patients," said R. Preston Mason, Ph.D., Brigham and Women's Hospital. "While emerging t

Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ:AMRN) ("Amarin" or the "Company"), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the "Board") 88 Harcourt Street Dublin 2, Ireland Members of the Board, We are meaningful shareholders of Amarin. While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Boa

DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL. "At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl product, to reduce cardiovascular (CV) events in at-risk patients," said Steve Ketchum, EVP, President of R&D and Chief Scientific Officer at Amarin. "With the advancement of additio

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced its intent to effect a ratio change on its American Depositary Shares ("ADS") from one (1) ADS representing one (1) ordinary share, to the new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 11, 2025 (the "Effective Date").​ The ordinary shares of Amarin Corporation (the "Company") will not be affected by this adjustment. The ADSs will continue to trade on The Nasdaq Capital Market under the symbol "AMRN".​ The objective of the Ratio Change is to increas

-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise -- -- Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the fourth quarter of 2024 and

10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

DEF 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

PRER14A - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

SCHEDULE 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13G - AMARIN CORP PLC\UK (0000897448) (Subject)

JP Morgan resumed coverage of Amarin with a rating of Underweight

Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

JP Morgan downgraded Amarin from Neutral to Underweight

SVB Leerink downgraded Amarin from Outperform to Mkt Perform and set a new price target of $3.00 from $10.00 previously

H.C. Wainwright downgraded Amarin from Buy to Neutral and set a new price target of $3.00 from $10.00 previously

Northland Capital downgraded Amarin from Outperform to Market Perform

SVB Leerink reiterated coverage of Amarin Corp with a rating of Outperform and set a new price target of $10.00 from $11.00 previously

SVB Leerink reiterated coverage of Amarin Corp with a rating of Outperform and set a new price target of $11.00 from $12.00 previously

SVB Leerink initiated coverage of Amarin Corp with a rating of Outperform and set a new price target of $12.00

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders

-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15. Mr. Provoost, who most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma, Inc., brings more than 20 years of corporate legal experience, having served most of his career in large and medium-sized pharmaceutical companies. "We are excited to welcome Jonathan to Amarin, where he will

DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role. Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience. He most recently served as president of Cordis, Cardinal Health's global interventional cardiovascular business where he led a turnaround of

Independent Report Acknowledges That Sarissa's Campaign to Remove Amarin's Chairman and De Facto Seize Board Control Would be Detrimental to Shareholder Value Board Urges Shareholders to Follow ISS and Glass Lewis's Recommendations and Vote "AGAINST" All of Sarissa's Proposals on the WHITE Proxy Card DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin" or the "Company") today announced that the leading independent proxy advisory firm, Institutional Shareholder Services ("ISS"), has recommended that shareholders vote "AGAINST" all of Sarissa's proposals on the WHITE proxy card at the upcoming General Meeting of Shareholder

Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting Amarin's Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders Vote the BLUE proxy card "FOR" the appointment of the Sarissa Nominees and "FOR" the Removal of Chairman Per Wold-Olsen on or before February 21, 2023 Sarissa Capital Management LP ("Sarissa") today issued the following letter to other shareholders of Amarin Corporation plc (NASDAQ:AMRN): Dear Fellow Amarin Shareholders: We, the owners, face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa/Vazkepa,

Vote the Blue Card "FOR" the appointment of the Sarissa Nominees to the Board Vote the Blue Card "FOR" the Removal of Chairman Per Wold-Olsen from the Board Sarissa Capital Management LP ("Sarissa") today issued the following letter to fellow shareholders of Amarin Corporation plc (NASDAQ:AMRN): Dear Fellow Amarin Shareholders: Amarin shareholders face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa/Vazkepa, a drug that can meaningfully reduce cardiovascular events in patients and save significant resources for health systems worldwide. The value of Vascepa, however, has been wasted by the company due to mismanagement and poo

Urges Shareholders to Vote "AGAINST" Sarissa's Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion and Operational and Financial Excellence Underscores Sarissa's Misguided Proxy Contest – Sarissa Has No Plan or New Ideas and Slate is Underqualified Company Launches www.voteamarin.com, Featuring Videos with Chairman, Per Wold-Olsen, and CEO, Karim Mikhail and Providing Additional Information for Shareholders DUBLIN, Ireland and BRIDGEWATER. N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corpo